Takeda Pharmaceutical Co. Ltd. and Pfizer have entered into an agreement under which Pfizer in China will co-promote Takeda’s Actos (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China. The exclusive co-promotion agreement will build on the current sales capability for Actos in China by increasing the number of medical representatives supporting the sales and marketing of the product and expanding the product reach utilizing the territory coverage of Pfizer in China, the largest multi...